Daily News Analysis

Issues with India’s Pharmaceutical sector

stylish_lining

Issues with India’s Pharmaceutical sector

Why in the News?

USFDA has issued a warning letter to a Gujarat-based Pharma manufacturing company citing serious violations of Good Manufacturing Practices (GMP).

India’s Pharma Sector:

  1. Indian pharma sector is set to achieve $130 billion by value, in the year 2030.
  2. The domestic Pharma companies are expected to report a steady revenue growth of 6-8 per cent in 2023-24.
  3. India is known as ‘the Pharmacy of the world’ as it is the world's third largest manufacturer of drugs by volume and second largest by value and known for its generic medicines and low-cost vaccines.
  4. India accounts for 60 percent of global vaccine production, contributing 40-70% of the WHO demand for DPT and BCG vaccines, and over 90% of the measles vaccine.
  5. The Exports of Pharmaceuticals have registered an increasing trend continuously for the past years.

 

 

 

 

Major segments of Indian Pharmaceutical Industry:

 

Generic drugs

      

 

 

Segments of Indian Pharmaceutical Industry

Research and Manufacturing

Biosimilars & Biologics

Over-the-Counter medicines

Bulk drugs

Vaccines

 

 

 

 

 

 

 

 

 

 

 

Challenges faced by the Pharma sector of India:

  1. Rising pressure from the US FDA:
    1. In 2018, USFDA inspections of Indian pharma manufacturing companies accounted for 14% of total FDA inspections across the world.
    2. Between 2013-18, 60 Drug good Manufacturing practices warning letters have been issued. This can potentially lead to,
      1. Negative impact on the share market value of Indian Pharma Companies.
      2. Hampering of the overall image of the pharma manufacturing quality.
  2. Government’s stringent control over the pricing of drugs turns out be a hurdle for the growth of innovative capabilities of Pharma companies, as the companies will restraint to invest in R&D activities as the assurance of getting the investment back through sale of drugs become bleak.
  3. Spurious drugs
    1. WHO reports that 35% of the world’s spurious drugs are produced in India, that are fake, counterfeit, or substandard.
    2. Gambia has made it mandatory for all Indian drugs to be tested before being exported to the African country since July 1, after Gambia reported death of dozens of children linked to consumption of cough syrup from India.
  4. Lack of skilled workforce:
    1. Gap between the theoretical degree studies and actual requirements of the industry, leading to a skill gap in spite of the fact that 4 lakh Pharma students graduate every year.
    2. This leads to sub-optimal utilisation and efficiency of the manpower.
    3. This also leads to Good Manufacturing Practices issues in the manufacturing processes.
  5. India’s high dependence on China for APIs:
    1. About 80% of India’s Active Pharmaceutical Ingredients’ (APIs), the raw materials used in the manufacture of medicines or formulations, requirements are fulfilled through imports from China.

Initiatives taken by India:

  1. PLI Scheme for Pharmaceuticals
    1. The scheme aims to enhance India’s manufacturing capabilities by increasing investment and production in the sector. This shall result in product diversification to high-value goods in the pharmaceutical sector.
    2. The scheme covers pharmaceutical goods under the following three categories-
      1. Category 1:

Biopharmaceuticals, Complex generic drugs, Patented drugs or drugs nearing patent expiry, Cell-based or gene therapy drugs, Orphan drugs, Special empty capsules, Complex excipients, Phyto-pharmaceuticals and other drugs as approved.

      1. Category 2:

Active Pharmaceutical Ingredients, Key Starting Materials and Drug Intermediates

      1. Category 3
        1. This includes Drugs not covered under Category 1 and Category 2.

Repurposed drugs, Auto-immune drugs, anti-cancer drugs, anti-diabetic drugs, anti-infective drugs, cardiovascular drugs, psychotropic drugs and anti-retroviral drugs, In-vitro diagnostic devices and other drugs not manufactured in India.

  1. Umbrella Scheme for Development of Pharmaceutical Industry
    1. A Central Sector Scheme namely ‘Strengthening of Pharmaceuticals Industry’ with three sub-schemes
      1. Assistance to Pharmaceutical Industry for Common Facilities (API-CF)
      2. Pharmaceutical Technology Upgradation Assistance Scheme (PTUAS)
      3. Pharmaceutical & Medical Devices Promotion and Development Scheme (PMPDS)
    2. The scheme intends to increase the efficiency and competitiveness of domestic pharmaceutical and MedTech industry in the global market.
    3. Also, to ensure accessibility, availability and affordability of quality pharmaceuticals and medical devices for mass consumption.
  2. Promotion of Bulk Drug Parks scheme
    1. Aims for creation of world class common infrastructure facilities to bulk drug units located in the parks.
    2. The Bulk Drug parks can
      1. bring down the manufacturing cost
      2. Increase competitiveness of the domestic bulk drug industry
      3. Minimize country’s dependence on imports by providing a push to indigenous manufacturing and facilitate Indian bulk drug industry.
  3. Establishment of Pharma Bureau
    1. Provides facilitation to investors and resolves issues of inter-departmental coordination in the Pharmaceutical and Medical Device sector.
    2. It also policy support to Department of Pharmaceuticals for framing incentive schemes for the industry.

Maharashtra Scraps Hindi as Compulsory Third Language

The Maharashtra government recently scrapped its Government Resolutions (GRs) that mandated Hindi as a compulsory third language from Grades 1 to 5 in Marathi and English medium schools. While the
Share It

Special Intensive Revision (SIR)

The Supreme Court (SC) is currently reviewing the Election Commission of India’s (ECI) process for the Special Intensive Revision (SIR) of electoral rolls in Bihar, suggesting that Aadhaar,
Share It

GM Crop

In ongoing trade talks, the United States is advocating for India to open its agriculture market to genetically modified (GM) crops. However, India has firmly rejected this proposal, citing concer
Share It

India-Brazil Relations

India and Brazil share a growing and dynamic bilateral relationship that has evolved across various sectors since the establishment of diplomatic ties in 1948. Their Strategic Partnership, formali
Share It

Legislative Productivity

The Lok Sabha Speaker’s remarks about the need to enhance legislative productivity reflect growing concerns about the diminishing effectiveness of India’s legislative bodies. The chall
Share It

Economic Growth

India's rapid urbanization is set to dramatically shape its future. The transformation of its cities holds immense potential for economic growth, but it also brings significant challenges. As
Share It

Global South

Prime Minister Narendra Modi's visit to Brazil from July 2-9, 2025, for the BRICS summit, was not only his longest international visit in 11 years but also marked a significant diplomatic outr
Share It

Maharashtra’s Special Public Security Bill, 2024

The Maharashtra Assembly has recently passed the Special Public Security Bill, 2024, aimed at combating “urban Maoism” and left-wing extremism in the state. The Bill criminalizes activ
Share It

Human Trafficking Networks and the 'Donkey Route'

The Enforcement Directorate (ED) and the National Investigation Agency (NIA) have launched aggressive probes into illegal human trafficking networks operating through the infamous "Donkey Rou
Share It

Patriot Air Defence Missile System (MIM-104)

Patriot Systems in Ukraine -The recent decision by the United States to send Patriot air defense systems to Ukraine amid growing Russian aggression underscores the system's strategic importanc
Share It

Newsletter Subscription


ACQ IAS
ACQ IAS